Jazz sues Avadel over Xyrem patent

Jazz Pharmaceuticals has claimed that Avadel Pharmaceuticals’ proposed narcolepsy drug infringes a patent related to Jazz’s blockbuster treatment Xyrem (sodium oxybate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Jazz Pharma accused of pay-for-delay deals over Xyrem

14 October 2021 Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem and hiked the drug prices to increase profits when it was on the verge of bankruptcy.

Big Pharma

English High Court denies Jazz units’ jurisdictional challenge

4 May 2022 Two subsidiaries of Ireland-based Jazz Pharmaceuticals have failed in their bid to challenge the jurisdiction of the English High Court in a dispute with Tokyo-headquartered Otsuka Pharmaceutical over a cannabis sativa collaboration.

Americas

FTC wades into escalating ‘Orange Book’ clash

15 November 2022 Jazz accused a rival of infringement | Avadel filed a counterclaim seeking to delist the patent from the Orange Book.